secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0000939767-23-000072
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis settles patent litigation with Teva; generic CABOMETYX license begins Jan 1, 2031
--------------------------------------------------------------------------------

- Settlement and License Agreement with Teva resolves patent litigation over generic CABOMETYX (cabozantinib).
- Teva may market generic cabozantinib from January 1, 2031, if FDA approved and subject to standard conditions.
- All pending Hatch-Waxman litigation between Exelixis and Teva in Delaware will be dismissed.
- Agreement is confidential and subject to review by FTC and DOJ.
- Expected to protect CABOMETYX exclusivity in the U.S. until at least January 1, 2031.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976723000072/0000939767-23-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976723000072/exel-20230718.htm
  HTML page:      https://secwatch.observer/filing/0000939767-23-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer